Sandoz to build Slovenian biosimilar development facility
European Pharmaceutical Review
JULY 21, 2023
To support future growth of its biosimilar pipeline, Sandoz is planning to build a Biosimilar Technical Development Center in Slovenia. The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026.
Let's personalize your content